X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 37.6 - View Chart
P/BV x 7.1 4.0 176.9% View Chart
Dividend Yield % 0.6 0.3 193.9%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-18
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589701 226.8%   
Low Rs1,232433 284.4%   
Sales per share (Unadj.) Rs417.5110.4 378.1%  
Earnings per share (Unadj.) Rs56.311.0 512.8%  
Cash flow per share (Unadj.) Rs64.717.2 375.6%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.4 255.2%  
Book value per share (Unadj.) Rs292.9158.8 184.5%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 65.8%   
Avg P/E ratio x25.151.6 48.5%  
P/CF ratio (eoy) x21.832.9 66.3%  
Price / Book Value ratio x4.83.6 134.9%  
Dividend payout %22.618.2 123.8%   
Avg Mkt Cap Rs m168,6531,360,021 12.4%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m9,17153,671 17.1%   
Avg. sales/employee Rs ThNM14,890.9-  
Avg. wages/employee Rs ThNM3,017.1-  
Avg. net profit/employee Rs ThNM1,480.6-  
INCOME DATA
Net Sales Rs m49,915264,895 18.8%  
Other income Rs m1,6458,388 19.6%   
Total revenues Rs m51,561273,282 18.9%   
Gross profit Rs m8,48256,081 15.1%  
Depreciation Rs m1,00614,998 6.7%   
Interest Rs m6715,176 13.0%   
Profit before tax Rs m8,45144,295 19.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m1,6068,452 19.0%   
Profit after tax Rs m6,73126,338 25.6%  
Gross profit margin %17.021.2 80.3%  
Effective tax rate %19.019.1 99.6%   
Net profit margin %13.59.9 135.6%  
BALANCE SHEET DATA
Current assets Rs m27,062316,359 8.6%   
Current liabilities Rs m15,324198,643 7.7%   
Net working cap to sales %23.544.4 52.9%  
Current ratio x1.81.6 110.9%  
Inventory Days Days6795 70.1%  
Debtors Days Days41108 38.3%  
Net fixed assets Rs m12,610213,178 5.9%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490378,606 9.1%   
Net worth Rs m35,027381,006 9.2%   
Long term debt Rs m1,21217,721 6.8%   
Total assets Rs m54,387643,028 8.5%  
Interest coverage x13.69.6 142.3%   
Debt to equity ratio x00 74.4%  
Sales to assets ratio x0.90.4 222.8%   
Return on assets %13.64.9 277.7%  
Return on equity %19.26.9 278.0%  
Return on capital %24.910.0 248.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56340,816 16.1%   
Fx outflow Rs m3,01230,143 10.0%   
Net fx Rs m3,55210,673 33.3%   
CASH FLOW
From Operations Rs m7,25939,072 18.6%  
From Investments Rs m1,864-33,708 -5.5%  
From Financial Activity Rs m-9,273-15,393 60.2%  
Net Cashflow Rs m-150-7,359 2.0%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - CADILA HEALTHCARE COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS